ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

Inclusion Criteria:

1. At least age of 18 years at screening;
2. Histologically or cytologically confirmed, locally advanced or metastatic solid tumorsfor which standard treatment either does not exist or has proven ineffective orunavailable or intolerable
3. At least one extra-cranial measurable lesion according to RECIST 1
4. Agree to provide fresh or archival tumor tissue
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1
6. Life expectancy >= 12 weeks
7. Agree to use medically accepted methods of contraception
8. Men or women should be using adequate contraceptive measures throughout the study;
9. Females subjects must not be pregnant at screening or have evidence ofnon-childbearing potential
10. Signed and dated Informed Consent Form

Exclusion Criteria: Any of the following would exclude the subject from participation in the study:

1. Treatment with any of the following:

• Previous or current treatment with B7-H3 targeted therapy
• Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14days prior to the first scheduled dose of HS-20093
• Prior treatment with a monoclonal antibody within 28 days prior to the firstscheduled dose of HS-20093
• Radiotherapy with a limited field of radiation for palliation within 2 weeks, orpatients received more than 30% of the bone marrow irradiation, or large-scaleradiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
• Major surgery within 4 weeks prior to the first scheduled dose of HS-20093

2. Subjects with previous or concurrent malignancies
3. Inadequate bone marrow reserve or organ dysfunction
4. Evidence of cardiovascular risk
5. Evidence of current severe or uncontrolled systemic diseases
6. Evidence of mucosal or internal bleeding within 1 month prior to the first scheduleddose of HS-20093
7. Known active infection requiring antibodies treatment within 2 weeks, or severeinfection within 4 weeks prior to the first scheduled dose of HS-20093
8. Subjects with current infectious diseases
9. History of neuropathy or mental disorders
10. Pregnant or lactating female
11. History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasyto drugs chemically related to HS-20093 or any of the components of HS-20093
12. Known vaccination or hypersensitivity of any level within 4 weeks prior to the firstscheduled dose of HS-20093
13. Unlikely to comply with study procedures, restrictions, and requirements in theopinion of the investigator
14. Any disease or condition that, in the opinion of the investigator, would compromisesubject safety or interfere with study assessments